Compare Stocks: DXR, CNXU, STIM, and PDEX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$8.89 -5.7%	$9.72	$6.85 ▼ $18.79	$237.88M	N/A	194,192 shs	395,039 shs
DXR Daxor	$10.00 -2.9%	$10.36	$8.56 ▼ $14.76	$58.38M	0.27	1,561 shs	2,016 shs
PDEX Pro-Dex	$65.67 -1.0%	$61.80	$23.47 ▼ $69.86	$209.67M	0.02	81,436 shs	33,039 shs
STIM Neuronetics	$3.00 -2.9%	$1.94	$0.80 ▼ $3.71	$228.59M	1.03	3.07 million shs	1.01 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	0.00%	-0.11%	-2.84%	-38.26%	+888,999,900.00%
DXR Daxor	0.00%	-2.15%	-4.32%	-5.44%	-6.37%
PDEX Pro-Dex	0.00%	-2.01%	+20.12%	+3.38%	+46.78%
STIM Neuronetics	0.00%	-9.09%	+59.57%	+150.00%	-9.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$8.89 -5.7%	$9.72	$6.85 ▼ $18.79	$237.88M	N/A	194,192 shs	395,039 shs
DXR Daxor	$10.00 -2.9%	$10.36	$8.56 ▼ $14.76	$58.38M	0.27	1,561 shs	2,016 shs
PDEX Pro-Dex	$65.67 -1.0%	$61.80	$23.47 ▼ $69.86	$209.67M	0.02	81,436 shs	33,039 shs
STIM Neuronetics	$3.00 -2.9%	$1.94	$0.80 ▼ $3.71	$228.59M	1.03	3.07 million shs	1.01 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	0.00%	-0.11%	-2.84%	-38.26%	+888,999,900.00%
DXR Daxor	0.00%	-2.15%	-4.32%	-5.44%	-6.37%
PDEX Pro-Dex	0.00%	-2.01%	+20.12%	+3.38%	+46.78%
STIM Neuronetics	0.00%	-9.09%	+59.57%	+150.00%	-9.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNXU Conexeu Sciences	2.00	Hold	$20.00	124.97% Upside
DXR Daxor	2.50	Moderate Buy	N/A	N/A
PDEX Pro-Dex	2.67	Moderate Buy	$70.00	6.59% Upside
STIM Neuronetics	2.50	Moderate Buy	$4.50	50.00% Upside

Current Analyst Ratings Breakdown

Latest DXR, CNXU, STIM, and PDEX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	CNXU Conexeu Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
8/11/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
8/6/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
7/21/2026	STIM Neuronetics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/20/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/17/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
7/1/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
6/29/2026	CNXU Conexeu Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	DXR Daxor	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
6/22/2026	CNXU Conexeu Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/18/2026	STIM Neuronetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A
PDEX Pro-Dex	$74.64M	2.81	$3.14 per share	20.94	$11.23 per share	5.85
STIM Neuronetics	$149.16M	1.53	N/A	N/A	$0.28 per share	10.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNXU Conexeu Sciences	-$3.92M	-$0.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/24/2026 (Estimated)
PDEX Pro-Dex	$8.98M	$3.62	18.14	23.62	N/A	16.08%	22.78%	14.30%	9/3/2026 (Estimated)
STIM Neuronetics	-$39M	-$0.44	N/A	N/A	N/A	-19.62%	-125.11%	-22.15%	11/3/2026 (Estimated)

Latest DXR, CNXU, STIM, and PDEX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/3/2026	Q4 2026	PDEX Pro-Dex	$0.67	N/A	N/A	N/A	$19.20 million	N/A
8/24/2026	Q2 2026	DXR Daxor	-$0.03	N/A	N/A	N/A	$2.80 million	N/A
8/11/2026	Q2 2026	STIM Neuronetics	-$0.1230	-$0.05	+$0.0730	-$0.05	$40.17 million	$41.57 million
6/15/2026	Q2 2026	CNXU Conexeu Sciences	N/A	-$0.11	N/A	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A
PDEX Pro-Dex	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNXU Conexeu Sciences	N/A	14.93	14.93
DXR Daxor	N/A	N/A	N/A
PDEX Pro-Dex	0.32	3.67	2.14
STIM Neuronetics	2.84	1.88	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNXU Conexeu Sciences	N/A
DXR Daxor	1.34%
PDEX Pro-Dex	15.28%
STIM Neuronetics	53.59%

Insider Ownership

Company	Insider Ownership
CNXU Conexeu Sciences	N/A
DXR Daxor	51.50%
PDEX Pro-Dex	45.90%
STIM Neuronetics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNXU Conexeu Sciences	4	26.76 million	N/A	N/A
DXR Daxor	37	5.84 million	2.83 million	Not Optionable
PDEX Pro-Dex	140	3.19 million	1.73 million	Not Optionable
STIM Neuronetics	180	76.20 million	69.80 million	Optionable

DXR, CNXU, STIM, and PDEX Headlines

Recent News About These Companies

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

August 18, 2026 | finance.yahoo.com

Neuronetics (NASDAQ:STIM) Major Shareholder Acquires 14,000 Shares of Stock

August 18, 2026 | insidertrades.com

Neuronetics (NASDAQ:STIM) Major Shareholder Buys $44,240.00 in Stock

August 17, 2026 | marketbeat.com

Neuronetics (NASDAQ:STIM) Stock Price Expected to Rise, BTIG Research Analyst Says

August 13, 2026 | americanbankingnews.com

Neuronetics, Inc. (STIM) Q2 FY2026 earnings call transcript

August 12, 2026 | finance.yahoo.com

Neuronetics Inc (STIM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Margin Expansion ...

August 12, 2026 | finance.yahoo.com

Neuronetics: Q2 Earnings Snapshot

August 11, 2026 | wtop.comW

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

August 11, 2026 | markets.businessinsider.com

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Neuronetics narrows Q2 loss as Greenbrook growth drives 9% revenue increase

August 11, 2026 | msn.com

BTIG Research Forecasts Strong Price Appreciation for Neuronetics (NASDAQ:STIM) Stock

August 11, 2026 | marketbeat.com

Neuronetics Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

August 11, 2026 | zacks.com

Neuronetics (NASDAQ:STIM) Announces Earnings Results

August 11, 2026 | marketbeat.com

Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA

August 11, 2026 | quiverquant.comQ

Malvern’s Neuronetics reaches deal with shareholder who pushed to break up company

August 5, 2026 | msn.com

Neuronetics and Jorey Chernett Announce Shared Vision

August 3, 2026 | globenewswire.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | globenewswire.com

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

July 28, 2026 | globenewswire.com

Neuronetics Opens Greenbrook Mental Wellness Centers National Center of Excellence in Rockville, Maryland

July 28, 2026 | quiverquant.comQ

Neuronetics Announces Date for Second Quarter 2026 Financial and Operating Results Conference Call

July 28, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DXR, CNXU, STIM, and PDEX Company Descriptions

Conexeu Sciences NASDAQ:CNXU

$8.89 -0.54 (-5.73%)

As of 08/21/2026 04:00 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Daxor NASDAQ:DXR

$10.00 -0.30 (-2.91%)

As of 08/21/2026 01:35 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Pro-Dex NASDAQ:PDEX

$65.67 -0.64 (-0.97%)

As of 08/21/2026 04:00 PM Eastern

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Neuronetics NASDAQ:STIM

$3.00 -0.09 (-2.91%)

As of 08/21/2026 04:00 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, CNXU, STIM, and PDEX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, CNXU, STIM, and PDEX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, CNXU, STIM, and PDEX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXR, CNXU, STIM, and PDEX Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Daxor NASDAQ:DXR

Pro-Dex NASDAQ:PDEX

Neuronetics NASDAQ:STIM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, CNXU, STIM, and PDEX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, CNXU, STIM, and PDEX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, CNXU, STIM, and PDEX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXR, CNXU, STIM, and PDEX Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Daxor NASDAQ:DXR

Pro-Dex NASDAQ:PDEX

Neuronetics NASDAQ:STIM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools